Making the ibVIS® Platform a One-Stop Solution and Strengthening Its Competitive Advantage

「Against this backdrop, in our platform business we used the enhanced aibVIS drug-discovery platform to advance the creation of mRNA-targeted small-molecule drugs through joint drug-discovery research with Toray Industries, Inc., Shionogi & Co., Ltd., RaQualia Pharma Inc. and Takeda Pharmaceutical Company Limited, with each project progressing smoothly.」

「By fundamentally improving the multiple rule-based AI systems that form the foundation of the platform and newly implementing multiple data-driven AI systems, we upgraded it to aibVIS, pronounced “AI-bVIS” and hereinafter referred to as the “aibVIS platform,” enabling more efficient and reliable mRNA-targeted drug discovery.」

「We believe that our ibVIS® platform incorporates all the drug-discovery and digital technologies required for mRNA-targeted small-molecule drug discovery, from “target discovery,” which comprehensively analyzes candidate substructures on mRNA that could serve as the “keyhole” for a small-molecule drug and determines the suitable “keyhole,” or target structure; to “screening,” which experimentally selects compounds that bind to the target structure from tens of thousands to hundreds of thousands of small-molecule compounds; to “hit-compound validation,” which examines in detail the binding strength and characteristics of hit compounds obtained through screening; and “lead-compound optimization,” which improves the efficacy of lead compounds obtained through hit-compound validation to the level required for a drug, ultimately obtaining drug-candidate compounds that can proceed to preclinical testing and beyond.」